Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Comparison of the Idylla™ Respiratory (IFV-RSV) panel with the GeneXpert Xpert® Flu/RSV assay: a retrospective study with nasopharyngeal and midturbinate samples.

Wouters Y, Keyaerts E, Rector A, Van Even E, Vissers S, Koletzki D, Pattery T, Rousseau E, Van Ranst M, Laffut W.

Diagn Microbiol Infect Dis. 2019 May;94(1):33-37. doi: 10.1016/j.diagmicrobio.2018.11.022. Epub 2018 Dec 4.

PMID:
30638655
2.

Diagnostic accuracy of digital RNA quantification versus real-time PCR for the detection of respiratory syncytial virus in nasopharyngeal aspirates from children with acute respiratory infection.

Bouzas ML, Oliveira JR, Queiroz A, Fukutani KF, Barral A, Rector A, Wollants E, Keyaerts E, Van der Gucht W, Van Ranst M, Beuselinck K, de Oliveira CI, Van Weyenbergh J, Nascimento-Carvalho CM; Acute Respiratory Infection and Wheeze Study Group Phase I and II.

J Clin Virol. 2018 Sep;106:34-40. doi: 10.1016/j.jcv.2018.07.003. Epub 2018 Jul 19.

PMID:
30031351
3.

Prevalence and seasonality of six respiratory viruses during five consecutive epidemic seasons in Belgium.

Ramaekers K, Keyaerts E, Rector A, Borremans A, Beuselinck K, Lagrou K, Van Ranst M.

J Clin Virol. 2017 Sep;94:72-78. doi: 10.1016/j.jcv.2017.07.011. Epub 2017 Jul 23.

PMID:
28772168
4.

In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model.

Houspie L, Stevens H, Ngotho M, Keyaerts E, Ispas G, Verloes R, Van Ranst M, Maes P.

Methods Mol Biol. 2013;1030:373-82. doi: 10.1007/978-1-62703-484-5_29.

PMID:
23821283
5.

Circulation of HRSV in Belgium: from multiple genotype circulation to prolonged circulation of predominant genotypes.

Houspie L, Lemey P, Keyaerts E, Reijmen E, Vergote V, Vankeerberghen A, Vaeyens F, De Beenhouwer H, Van Ranst M.

PLoS One. 2013;8(4):e60416. doi: 10.1371/journal.pone.0060416. Epub 2013 Apr 5.

6.

Susceptibility of the PER.C6 cell line for infection with clinical human respiratory syncytial virus isolates.

Houspie L, Keyaerts E, Maes P, Van Ranst M.

J Virol Methods. 2012 Apr;181(1):37-42. doi: 10.1016/j.jviromet.2012.01.008. Epub 2012 Jan 25.

PMID:
22305961
7.

Exhaled breath condensate sampling is not a new method for detection of respiratory viruses.

Houspie L, De Coster S, Keyaerts E, Narongsack P, De Roy R, Talboom I, Sisk M, Maes P, Verbeeck J, Van Ranst M.

Virol J. 2011 Mar 4;8:98. doi: 10.1186/1743-422X-8-98.

8.

Studies of Antiviral Activity and Cytotoxicity of Wrightia tinctoria and Morinda citrifolia.

Selvam P, Murugesh N, Witvrouw M, Keyaerts E, Neyts J.

Indian J Pharm Sci. 2009 Nov;71(6):670-2. doi: 10.4103/0250-474X.59550.

9.

Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.

Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P.

Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21. doi: 10.1128/AAC.01509-08. Epub 2009 Jun 8.

10.

Replication reduction neutralization test, a quantitative RT-PCR-based technique for the detection of neutralizing hantavirus antibodies.

Maes P, Keyaerts E, Li S, Nlandu-Masunda V, Clement J, Van Ranst M.

J Virol Methods. 2009 Aug;159(2):295-9. doi: 10.1016/j.jviromet.2009.04.006. Epub 2009 May 3.

PMID:
19406158
11.

A pancoronavirus RT-PCR assay for detection of all known coronaviruses.

Vijgen L, Moës E, Keyaerts E, Li S, Van Ranst M.

Methods Mol Biol. 2008;454:3-12. doi: 10.1007/978-1-59745-181-9_1.

PMID:
19057882
12.

Truncated recombinant puumala virus nucleocapsid proteins protect mice against challenge in vivo.

Maes P, Clement J, Cauwe B, Bonnet V, Keyaerts E, Robert A, Van Ranst M.

Viral Immunol. 2008 Mar;21(1):49-60. doi: 10.1089/vim.2007.0059.

PMID:
18355122
13.

In Vitro Antiviral Activity of some Novel Isatin Derivatives against HCV and SARS-CoV Viruses.

Selvam P, Murgesh N, Chandramohan M, De Clercq E, Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV.

Indian J Pharm Sci. 2008 Jan;70(1):91-4. doi: 10.4103/0250-474X.40339.

14.

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.

Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, Egberink H, Balzarini J, Van Ranst M.

Antiviral Res. 2007 Sep;75(3):179-87. Epub 2007 Mar 30.

PMID:
17428553
15.

Evaluation of the efficacy of disinfectants against Puumala hantavirus by real-time RT-PCR.

Maes P, Li S, Verbeeck J, Keyaerts E, Clement J, Van Ranst M.

J Virol Methods. 2007 Apr;141(1):111-5. Epub 2006 Dec 22.

PMID:
17188760
16.

Evolutionary history of the closely related group 2 coronaviruses: porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, and human coronavirus OC43.

Vijgen L, Keyaerts E, Lemey P, Maes P, Van Reeth K, Nauwynck H, Pensaert M, Van Ranst M.

J Virol. 2006 Jul;80(14):7270-4.

17.

Truncated recombinant Dobrava hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice.

Maes P, Keyaerts E, Bonnet V, Clement J, Avsic-Zupanc T, Robert A, Van Ranst M.

Intervirology. 2006;49(5):253-60. Epub 2006 May 22.

PMID:
16714853
18.

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, Printsevskaya SS, Olsufyeva EN, Solovieva SE, Preobrazhenskaya MN.

Antiviral Res. 2006 Oct;72(1):20-33. Epub 2006 Apr 6.

PMID:
16675038
19.

Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture.

Balzarini J, Keyaerts E, Vijgen L, Vandermeer F, Stevens M, De Clercq E, Egberink H, Van Ranst M.

J Antimicrob Chemother. 2006 Mar;57(3):472-81. Epub 2005 Dec 30.

PMID:
16387746
20.
21.

Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR.

Keyaerts E, Vijgen L, Maes P, Duson G, Neyts J, Van Ranst M.

Int J Infect Dis. 2006 Jan;10(1):32-7. Epub 2005 Jul 14.

22.

Circulation of genetically distinct contemporary human coronavirus OC43 strains.

Vijgen L, Keyaerts E, Lemey P, Moës E, Li S, Vandamme AM, Van Ranst M.

Virology. 2005 Jun 20;337(1):85-92.

23.

Growth kinetics of SARS-coronavirus in Vero E6 cells.

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):1147-51.

PMID:
15752773
24.

Genetic variability of human respiratory coronavirus OC43.

Vijgen L, Lemey P, Keyaerts E, Van Ranst M.

J Virol. 2005 Mar;79(5):3223-4; author reply 3224-5. No abstract available.

25.

A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium.

Moës E, Vijgen L, Keyaerts E, Zlateva K, Li S, Maes P, Pyrc K, Berkhout B, van der Hoek L, Van Ranst M.

BMC Infect Dis. 2005 Feb 1;5:6.

26.

Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event.

Vijgen L, Keyaerts E, Moës E, Thoelen I, Wollants E, Lemey P, Vandamme AM, Van Ranst M.

J Virol. 2005 Feb;79(3):1595-604.

27.

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M.

Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8.

PMID:
15351731
28.

Detection of Puumala hantavirus antibody with ELISA using a recombinant truncated nucleocapsid protein expressed in Escherichia coli.

Maes P, Keyaerts E, Clement J, Bonnet V, Robert A, Van Ranst M.

Viral Immunol. 2004;17(2):315-21.

PMID:
15279709
29.

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound.

Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M.

Int J Infect Dis. 2004 Jul;8(4):223-6.

30.

Identification of six new polymorphisms in the human coronavirus 229E receptor gene (aminopeptidase N/CD13).

Vijgen L, Keyaerts E, Zlateva K, Van Ranst M.

Int J Infect Dis. 2004 Jul;8(4):217-22.

31.

Plasma exchange-associated immunoglobulin m-negative hantavirus disease after a camping holiday in southern france.

Keyaerts E, Ghijsels E, Lemey P, Maes P, Zachée P, Daelemans R, Vervoort T, Mertens G, Van Ranst M, Clement J.

Clin Infect Dis. 2004 May 15;38(10):1350-6. Epub 2004 Apr 26.

PMID:
15156469
32.

Hantavirus infections in Europe.

Clement J, Lameire N, Keyaerts E, Maes P, Van Ranst M.

Lancet Infect Dis. 2003 Dec;3(12):752-3; discussion 753-4. No abstract available.

PMID:
14652198
33.

Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals.

Struyf F, Posavad CM, Keyaerts E, Van Ranst M, Corey L, Spear PG.

J Infect Dis. 2002 Jan 1;185(1):36-44. Epub 2001 Dec 14.

PMID:
11756979
34.

Characterization of a cDNA encoding the bovine coxsackie and adenovirus receptor.

Thoelen I, Keyaerts E, Lindberg M, Van Ranst M.

Biochem Biophys Res Commun. 2001 Nov 9;288(4):805-8.

PMID:
11688979
35.

Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease.

Rector A, Lemey P, Laffut W, Keyaerts E, Struyf F, Wollants E, Vermeire S, Rutgeerts P, Van Ranst M.

Genes Immun. 2001 Oct;2(6):323-8.

36.

Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease.

Rector A, Vermeire S, Thoelen I, Keyaerts E, Struyf F, Vlietinck R, Rutgeerts P, Van Ranst M.

Hum Genet. 2001 Mar;108(3):190-3.

PMID:
11354628
37.

Prevalence of CCR5 and CCR2 HIV-coreceptor gene polymorphisms in Belgium.

Struyf F, Thoelen I, Charlier N, Keyaerts E, Van der Donck I, Wuu J, Van Ranst M.

Hum Hered. 2000 Sep-Oct;50(5):304-7.

PMID:
10878474

Supplemental Content

Loading ...
Support Center